Alimera Sciences Announces Study of Iluvien® in Patients With Macular Edema Due to Retinal Vein Occlusion
September 27, 2009
Alimera Sciences, Inc. has announced that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien® in patients with macular edema secondary to retinal vein occlusion. The randomized, double-masked trial is called FAVOR (Fluocinolone Acetonide for Vein Occlusion in Retina) and compares two doses of Iluvien (0.23 and 0.45 micrograms per day).
A global clinical study, the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) Study is already underway for the treatment of diabetic macular edema.
Iluvien is an investigative, extended release intravitreal insert that delivers fluocinolone acetonide. Iluvien is only 3.5mm in length and 0.37mm in diameter. Each Iluvien insert is designed to provide a sustained therapeutic effect of up to 36 months, for the low dose of Iluvien, and up to 24 months, for the high dose of Iluvien. The insert is placed into the patient’s eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intravitreal injection.
Read the release.
Comments
Jump down to form below to submit your own comments
One Response to “Alimera Sciences Announces Study of Iluvien® in Patients With Macular Edema Due to Retinal Vein Occlusion”
